{
    "Title": "Human leishmaniasis vaccines: Use cases, target population and potential global demand",
    "URL": "https://doi.org/10.1371/journal.pntd.0009742",
    "Published": "September 21, 2021",
    "Subject_Areas": [
        "Leishmaniasis",
        "Vaccines",
        "Vaccine development",
        "Prophylaxis",
        "Vaccination and immunization",
        "Medical risk factors",
        "Public and occupational health",
        "Epidemiology"
    ],
    "Authors": {
        "Stefano Malvolti": [
            "MMGH Consulting, Zurich, Switzerland"
        ],
        "Melissa Malhame": [
            "MMGH Consulting, Zurich, Switzerland"
        ],
        "Carsten F. Mantel": [
            "MMGH Consulting, Zurich, Switzerland"
        ],
        "Epke A. Le Rutte": [
            "Department of Epidemiology and Public Health, Swiss Tropical and Public Health Institute, Basel, Switzerland; Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands"
        ],
        "Paul M. Kaye": [
            "York Biomedical Research Institute, Hull York Medical School, University of York, Heslington, York, United Kingdom"
        ]
    }
}